Improving quality of life for blood cancer patients receiving cellular therapy
Official title: Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study
Run by Massachusetts General Hospital · NCT05646576 · Data updated 2026-11-12
This study is testing a new palliative care program called PEACE to see if it can improve the quality of life for blood cancer patients getting cellular therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | December 30, 2022 |
| Main results expected | December 30, 2026 |
| Study ends | April 1, 2027 |
| Registry record updated | April 21, 2026 |
| Trial ID | NCT05646576 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with a hematologic malignancy who are receiving autologous adoptive cellular therapy at Massachusetts General Hospital.
✕Probably not a fit
Patients with impaired cognition or uncontrolled mental illness, or those already receiving palliative care, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of a palliative care intervention, known as PEACE, in enhancing the quality of life for patients with hematologic malignancies such as Lymphoma, Leukemia, or Multiple Myeloma who are undergoing adoptive cellular therapy. Initially, a pilot phase will involve 10 participants receiving the intervention, followed by a randomized assignment of 80 participants into two groups: one receiving the palliative care intervention alongside standard oncology care, and the other receiving only standard care. The study will last up to 2 years and is supported by the American Society of Clinical Oncology.
Why it matters
Potential benefit: If successful, this study could significantly improve the quality of life and overall experiences of patients undergoing adoptive cellular therapy for blood cancers.
How similar studies have gone: Other studies have shown promising results with palliative care interventions in oncology, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older. * Ability to complete surveys in English or with assistance of an interpreter. * Diagnosis of a hematologic malignancy. * Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product. Exclusion Criteria: * Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment. * Already receiving palliative care (PC).
Where it's running
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Patrick C Johnson, MD — Massachusetts General Hospital
- Study coordinator: Patrick C Johnson
- Email: PCJOHNSON@MGH.HARVARD.EDU
- Phone: 617-724-4000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving outcomes for stem cell transplant patients using an intervention website
This study is testing if a special website can help adults with blood cancer feel better and improve their quality of life after a stem cell transplant compared to a regular educational website.
-
Improving leukemia diagnosis using artificial intelligence
This study is testing whether an artificial intelligence system can improve the diagnosis of leukemia by comparing its accuracy and speed to traditional methods using a large set of blood samples.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau
This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.
-
Telehealth music therapy for cognitive difficulties in blood cancer survivors
This program will test whether telehealth music therapy can help adults who survived leukemia, lymphoma, or myeloma and who are having trouble with memory, attention, or thinking.
-
Best germline DNA source to guide drug dosing after allogeneic stem cell transplant
This project will test whether blood, skin, or other tissue samples give the most reliable genetic information to guide medicine dosing for adults who receive an allogeneic stem cell transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.